EXAS · EXACT SCIENCES CORP
Shares
190.89M
No Price Data
No daily price data is available for this stock yet. Data syncs automatically from Yahoo Finance.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Feb 13, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Limited
Momentum
Limited
Sentiment
Bearish
Fundamentals
Excellent
Quant / Vol
Limited
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
Not enough data for a confident read.
Momentum
relative strength
Not enough data for a confident read.
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Distributing
-80% holders QoQ · +1 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.11% of float · ▲ +5.9% MoM · 3.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
2 holders — near 3-yr low, contrarian setup
Fundamentals
Revenue growth
0%
Y/Y
Gross margin
54603%
expanding
EPS growth
+80%
Y/Y
Free cash flow
$356.8M
Balance sheet
$905.2M
net cash
Quant / Vol
risk profile
Not enough data for a confident read.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Jun 30, 2025
in total
Restructuring and transformation costs
$105M – $120M
in 2026
Annual savings
$150M
Prior guidance
period ended
· from the 8-K filed Nov 3, 2025
Total revenue
· full-year 2025
$3.22B – $3.24B
Screening
· full-year 2025
$2.51B – $2.52B
Precision Oncology
· full-year 2025
$710M – $715M
Adjusted EBITDA
· full-year 2025
$470M – $480M
Guided vs delivered
· last 4 settled
Total revenue
full-year 2025
guided $3.22B – $3.24B
$3.25B
Beat +0.6%
Total revenue
the first quarter
guided $615M – $630M
$637.52M
Beat +2.4%
Total revenue
the year
guided $2.81B – $2.85B
$2.76B
Miss −2.5%
Total revenue
for the year
guided $2.48B – $2.49B
$2.5B
Beat +0.8%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $400M | Full Year 2025 | — |
| Adjusted EBITDA margin non-GAAP | 7% | Q4 2025 | — |
| Adjusted gross margin non-GAAP | 73% | Q4 2025 | — |
| Free cash flow non-GAAP | $357M | Full Year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Key facts
CIK
1124140
CUSIP
30063P105
13F (30d)
43 filings
7 filers
Visit website
Investor relations